318 related articles for article (PubMed ID: 28145031)
1. Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.
Gostelow R; Scudder C; Keyte S; Forcada Y; Fowkes RC; Schmid HA; Church DB; Niessen SJ
J Vet Intern Med; 2017 Mar; 31(2):355-364. PubMed ID: 28145031
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide for the Medical Management of Feline Hypersomatotropism.
Scudder CJ; Gostelow R; Forcada Y; Schmid HA; Church D; Niessen SJ
J Vet Intern Med; 2015; 29(4):1074-80. PubMed ID: 25945588
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
Tahara S; Murakami M; Kaneko T; Shimatsu A
Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
[TBL] [Abstract][Full Text] [Related]
4. Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.
Scudder CJ; Hazuchova K; Gostelow R; Church DB; Forcada Y; Fowkes RC; Niessen SJ
J Feline Med Surg; 2021 Feb; 23(2):131-137. PubMed ID: 32684121
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism.
Miceli DD; García JD; Pompili GA; Rey Amunategui JP; Ferraris S; Pignataro OP; Guitelman M
J Feline Med Surg; 2022 Dec; 24(12):1238-1244. PubMed ID: 35133181
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
7. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.
Fleseriu M; Rusch E; Geer EB;
Endocrine; 2017 Jan; 55(1):247-255. PubMed ID: 27896545
[TBL] [Abstract][Full Text] [Related]
11. Exogenous insulin treatment after hypofractionated radiotherapy in cats with diabetes mellitus and acromegaly.
Dunning MD; Lowrie CS; Bexfield NH; Dobson JM; Herrtage ME
J Vet Intern Med; 2009; 23(2):243-9. PubMed ID: 19192146
[TBL] [Abstract][Full Text] [Related]
12. Serum N-Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism.
Keyte SV; Kenny PJ; Forcada Y; Church DB; Niessen SJ
J Vet Intern Med; 2016 Jul; 30(4):973-82. PubMed ID: 27425382
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of IGF-1 levels in cats with transient and permanent diabetes mellitus.
Alt N; Kley S; Tschuor F; Zapf J; Reusch CE
Res Vet Sci; 2007 Dec; 83(3):331-5. PubMed ID: 17367830
[TBL] [Abstract][Full Text] [Related]
14. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
15. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus.
Linari G; Fleeman L; Gilor C; Giacomelli L; Fracassi F
J Feline Med Surg; 2022 Feb; 24(2):168-176. PubMed ID: 34009061
[TBL] [Abstract][Full Text] [Related]
17. Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats.
Nelson RW; Henley K; Cole C;
J Vet Intern Med; 2009; 23(4):787-93. PubMed ID: 19566845
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
[TBL] [Abstract][Full Text] [Related]
19. Measurements of growth hormone and insulin-like growth factor 1 in cats with diabetes mellitus.
Reusch CE; Kley S; Casella M; Nelson RW; Mol J; Zapf J
Vet Rec; 2006 Feb; 158(6):195-200. PubMed ID: 16474053
[TBL] [Abstract][Full Text] [Related]
20. Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus.
Strage EM; Sundberg M; Holst BS; Andersson Franko M; Ramström M; Fall T; Lewitt M
J Vet Intern Med; 2018 Sep; 32(5):1579-1590. PubMed ID: 30112786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
